E-viri
Recenzirano
Odprti dostop
-
Eggermont, Alexander M.M; Chiarion-Sileni, Vanna; Grob, Jean-Jacques; Dummer, Reinhard; Wolchok, Jedd D; Schmidt, Henrik; Hamid, Omid; Robert, Caroline; Ascierto, Paolo A; Richards, Jon M; Lebbé, Céleste; Ferraresi, Virginia; Smylie, Michael; Weber, Jeffrey S; Maio, Michele; Bastholt, Lars; Mortier, Laurent; Thomas, Luc; Tahir, Saad; Hauschild, Axel; Hassel, Jessica C; Hodi, F. Stephen; Taitt, Corina; de Pril, Veerle; de Schaetzen, Gaetan; Suciu, Stefan; Testori, Alessandro
The New England journal of medicine, 11/2016, Letnik: 375, Številka: 19Journal Article
Patients with surgically resected stage III melanoma are at high risk for recurrence. The 5-year survival rate with ipulimumab was 11 percentage points higher than that with placebo (65% vs. 54%), but there were substantial immune-related toxic effects. Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4) to augment antitumor immune responses, was approved by the Food and Drug Administration (FDA) and the European Medicines Agency in 2011 at a dose of 3 mg per kilogram of body weight for the treatment of advanced melanoma. 1 , 2 On the basis of data from a phase 2 trial that indicated the potential for a dose of 10 mg per kilogram to have higher efficacy than the dose of 0.3 mg or 3 mg per kilogram in patients with advanced melanoma, although at a cost of more . . .
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.